HLS Therapeutics Has Entered Into A Product Listing Agreement With The Province Of Alberta, For The Listing And Public Reimbursement Of Amarin's Vascepa (Icosapent Ethyl), Effective August 1, 2024
Portfolio Pulse from Benzinga Newsdesk
HLS Therapeutics has entered into a Product Listing Agreement with the Province of Alberta for the listing and public reimbursement of Amarin's Vascepa, effective August 1, 2024. Vascepa will be reimbursed for secondary prevention of cardiovascular events in statin-treated patients with established cardiovascular disease and elevated triglycerides.
July 29, 2024 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amarin's Vascepa will be listed and publicly reimbursed in Alberta starting August 1, 2024, for secondary prevention of cardiovascular events in statin-treated patients with established cardiovascular disease and elevated triglycerides.
The agreement with Alberta for the listing and reimbursement of Vascepa is a positive development for Amarin, potentially increasing its market reach and revenue. The news is likely to have a positive short-term impact on Amarin's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80